Search Results for 'biosimilars reference'
biosimilars reference published presentations and documents on DocSlides.
US Regulatory Pathway For Biosimilars
by cheryl-pisano
Practical Legal/Regulatory Considerations Arising...
Biosimilars & EU regulation
by karlyn-bohler
Alice DOMINIQUE - M2 AREIPS. 1. Content. 2. Defin...
Biosimilars in the united states – Update on FDA Impleme
by test
James C. Shehan. Hyman, Phelps & McNamara, P....
Challenges in demonstrating biosimilarity and interchangeability of biosimilar products
by calandra-battersby
OMICS Group Biosimilars 2015 Birmingham, UK. 10-1...
Distinguishable INNs: A Global Solution
by trish-goza
Richard . Dolinar. , MD. Chairman, Alliance for S...
Acceptable changes in quality attributes of glycosylated bi
by debby-jeon
Schiestl M, Stangler T, Torella C, et al. . Nat B...
Biological Products: concepts, naming,
by faustina-dinatale
interchangeability,extrapolation. and safety. Dr...
Budget impact and cost-effectiveness of oncology
by roxanne
biosimilars. Prof. dr. Steven Simoens. Health econ...
Considerations with the Adoption of Biosimilars
by ellena-manuel
Considerations with the Adoption of Biosimilars Ja...
Challenges in demonstrating biosimilarity and interchangeability of biosimilar products
by stefany-barnette
OMIC Group Biosimilars 2014. Hyderabad India. 27-...
JMP for Biosimilars : Tools for Analytical Similarity
by erica
Sept 16, 2015. W. Heath Rushing, . Adsurgo. LLC. ...
Comparison of US/EU Biosimilar
by myesha-ticknor
Guidelines. Kamali Chance, MPH, PhD, RAC. Senior...
Biosimilars Guideline – a Summary of the Industry Comments
by marina-yarberry
M Bredenhann | Nycomed | 19.11.10. BIOSIMILAR...
Comparison of US/EU Biosimilar
by danika-pritchard
Guidelines. Kamali Chance, MPH, PhD, RAC. Senior...
Phil Johnson MS RPh Safe School Meds, Principle Partner
by yoshiko-marsland
Moffitt Cancer Center, Director of Pharmacy (Reti...
Category 1: Defining Terms Clue: A biologic
by myesha-ticknor
Category 1: Defining Terms Clue: A biologic produc...